SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Respiratory Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pelaia, G.
Right arrow Articles by Maselli, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pelaia, G.
Right arrow Articles by Maselli, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Omalizumab in the treatment of severe asthma: efficacy and current problems

Girolamo Pelaia

Department of Experimental and Clinical Medicine, Section of Respiratory Diseases, University Magna Græcia of Catanzaro, Italy, pelaia{at}unicz.it

Teresa Renda

Department of Experimental and Clinical Medicine, Section of Respiratory Diseases, University Magna Græcia of Catanzaro, Italy

Pasquale Romeo

Department of Experimental and Clinical Medicine, Section of Respiratory Diseases, University Magna Græcia of Catanzaro, Italy

Maria Teresa Busceti

Department of Experimental and Clinical Medicine, Section of Respiratory Diseases, University Magna Græcia of Catanzaro, Italy

Rosario Maselli

Department of Experimental and Clinical Medicine, Section of Respiratory Diseases, University Magna Græcia of Catanzaro, Italy

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the treatment of severe allergic asthma. This drug inhibits allergic responses by binding to serum IgE, thus preventing their interactions with cellular IgE receptors. Omalizumab is also capable of downregulating the expression of high-affinity IgE receptors on inflammatory cells, as well as the numbers of eosinophils in both blood and induced sputum. The clinical effects of omalizumab include relevant improvements in respiratory symptoms and quality of life, paralleled by a marked reduction of asthma exacerbations, emergency room visits, and use of systemic corticosteroids and rescue bronchodilators. Omalizumab is relatively well tolerated, and only rarely induces anaphylactic reactions. Therefore, this drug represents a valid option as add-on therapy for patients with severe persistent allergic asthma, inadequately controlled by high doses of standard inhaled treatments.

Key Words: omalizumab • anti-IgE • severe asthma

Therapeutic Advances in Respiratory Disease, Vol. 2, No. 6, 409-421 (2008)
DOI: 10.1177/1753465808100431
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Evid Based Complement Alternat MedHome page
T. Nagai, M. Nakao, Y. Shimizu, Y. Kodera, M. Oh-Ishi, T. Maeda, and H. Yamada
Proteomic Analysis of Anti-inflammatory Effects of a Kampo (Japanese Herbal) Medicine 'Shoseiryuto (Xiao-Qing-Long-Tang)' on Airway Inflammation in a Mouse Model
Evid. Based Complement. Altern. Med., October 27, 2009; (2009) nep151v1.
[Abstract] [Full Text] [PDF]


Advertisement